Antares Pharma, Inc. (NASDAQ:ATRS)‘s stock had its “buy” rating reiterated by investment analysts at Piper Jaffray Companies in a report released on Friday.

Other equities analysts also recently issued reports about the company. Vetr upgraded Antares Pharma from a “hold” rating to a “buy” rating and set a $3.30 target price for the company in a research note on Wednesday, July 5th. Chardan Capital started coverage on Antares Pharma in a research note on Friday, June 23rd. They issued a “buy” rating and a $5.00 target price for the company. Finally, HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Antares Pharma in a research note on Friday, June 23rd. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and two have issued a strong buy rating to the stock. Antares Pharma currently has an average rating of “Buy” and a consensus price target of $4.34.

Antares Pharma (ATRS) traded up 0.66% during mid-day trading on Friday, reaching $3.04. The company’s stock had a trading volume of 735,465 shares. Antares Pharma has a 12 month low of $1.27 and a 12 month high of $3.37. The stock’s 50-day moving average is $3.07 and its 200-day moving average is $2.88. The firm’s market capitalization is $475.48 million.

Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.03) by $0.01. The business had revenue of $13.42 million during the quarter, compared to the consensus estimate of $12.99 million. Antares Pharma had a negative return on equity of 41.37% and a negative net margin of 34.27%. On average, equities analysts anticipate that Antares Pharma will post ($0.11) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Antares Pharma, Inc. (ATRS) Receives “Buy” Rating from Piper Jaffray Companies” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/09/antares-pharma-inc-atrs-receives-buy-rating-from-piper-jaffray-companies.html.

Hedge funds have recently modified their holdings of the business. Alliancebernstein L.P. acquired a new position in Antares Pharma in the second quarter valued at approximately $119,000. Legal & General Group Plc acquired a new position in Antares Pharma in the second quarter valued at approximately $120,000. MML Investors Services LLC boosted its stake in Antares Pharma by 228.2% in the second quarter. MML Investors Services LLC now owns 43,147 shares of the specialty pharmaceutical company’s stock valued at $139,000 after acquiring an additional 30,000 shares during the period. Credit Suisse AG acquired a new position in Antares Pharma in the first quarter valued at approximately $146,000. Finally, Arrowstreet Capital Limited Partnership acquired a new position in Antares Pharma in the second quarter valued at approximately $174,000. Institutional investors own 36.79% of the company’s stock.

About Antares Pharma

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.